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Background: Clinical studies indicate that post-traumatic stress disorder (PTSD) frequently shares co-morbidity with
chronic pain. Although in animals acute stress-induced antinociception is well documented, the effect of PTSD-like
stress on nociceptive sensitivity is unclear. Though a few studies measured nociceptive responses at a single time
point, no studies have examined changes in nociceptive sensitivity over time following exposure to PTSD-like stress.
Nociceptin/orphanin FQ (N/OFQ), an endogenous ligand for the N/OFQ peptide (NOP) receptor, modulates various
biological functions in the central nervous system that are affected by PTSD, including nociceptive sensitivity, stress
and anxiety, learning and memory.
Results: The present study examined thermal and mechanical nociceptive sensitivity in male Sprague Dawley rats
between 7 and 28 days after single-prolonged stress (SPS), an established animal model for PTSD. Rat paw
withdrawal thresholds (PWT) to von Frey and paw withdrawal latencies (PWL) to radiant heat stimuli, respectively,
dramatically decreased as early as 7 days after initiation of SPS and lasted the length of the study, 28 days. In
addition, N/OFQ levels increased in cerebrospinal fluid (CSF; on days 9, 14 and 28) and serum (day 28), while levels
of circulating corticosterone (CORT) decreased 28 days after initiation of SPS. SPS exposure induced anxiety-like
behavior and enhanced inhibition of the hypothalamo-pituitary-adrenal (HPA) axis, as previously reported for
this model.
Conclusions: Our results demonstrate that SPS induces the development of persistent mechanical allodynia and
thermal hyperalgesia that is accompanied by increased N/OFQ content in the CSF, and eventually, in serum. These
findings suggest a link between N/OFQ and the development of hyperalgesia and allodynia in a rat model of PTSD.
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Numerous clinical studies reported co-occurrence of
PTSD with chronic pain [for review see 1], but the
source of the pain is not always an obvious one. In one
study of U.S. veterans, 66% of PTSD patients were diag-
nosed with chronic pain [2]. A recent investigation
revealed 58.6% of 340 Operation Enduring Freedom/
Operation Iraqi Freedom (OEF/OIF) veterans developed
both chronic pain and PTSD [3]. Assessment of pain* Correspondence: Kelly-Standifer@ouhsc.edu
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reproduction in any medium, provided the orsensitivity in PTSD patients suggests that PTSD can be
associated with both increases and decreases in experi-
mental pain sensitivity [1,4]. Acute stress-induced anti-
nociception is well known in animals, whereas chronic
stress is often associated with hyperalgesia [5-8]. How-
ever, our understanding about chronic pain and PTSD,
and the ability of PTSD to alter pain sensitivity is limited
due to the difficulty of translation from animal models
of PTSD to human studies. Studies specifically examin-
ing the temporal dynamics of sensitivity to nociceptive
stimuli following exposure to a PTSD-inducing event are
lacking, thus limiting our search for effective therapies
for both pain and PTSD. SPS, an established animal
model for PTSD [9,10], mimics some of the physio-
logical and behavioral changes described in PTSDLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Experimental paradigm. Rats were assessed for baseline
pain thresholds prior to SPS initiation at day 0. After 7 days of
isolation, pain sensitivity (P) was monitored by assessment of
nociceptive responses to mechanical and thermal stimuli on days 7,
9, 12, 14, 18, 21 and 28. Anxiety-like behavior (A) was tested by EPM
on day 9 or 14, but not necessarily in rats that were euthanized on
those days. Rats were euthanized (*) at day 9, 15 or 28. Sera and CSF
samples were taken immediately for further analysis.
Zhang et al. Molecular Pain 2012, 8:76 Page 2 of 10
http://www.molecularpain.com/content/8/1/76patients that includes enhanced negative feedback to the
HPA axis, anxiety behavior and cognitive impairments
[11-14]. More importantly, SPS produces a PTSD-like
state without subjecting animals to foot shock, thus fa-
cilitating assessment of nociception by paw withdrawal
methods. Therefore, the first goal of this study was to
determine if subjecting rats to PTSD-like conditions
using the SPS model alters nociceptive sensitivity to
mechanical and thermal stimuli over time.
Nociceptin/orphanin FQ (N/OFQ) [15,16] an en-
dogenous ligand for the N/OFQ peptide (NOP) receptor,
modulates various biological functions in the CNS, in-
cluding nociceptive sensitivity, stress, anxiety, learning,
memory and cytokine release [17]; all of which are
affected by PTSD. Evidence from several studies suggests
that the N/OFQ-NOP receptor system plays an import-
ant role in stress-related behaviors and activation of
the HPA axis. Intracerebroventricular (icv) injection of
N/OFQ elevates circulating adrenocorticotropic hor-
mone (ACTH) and CORT levels in unstressed and
mildly stressed rats, as well as produces anxiogenic
effects [18-20]. However, anxiolytic effects following icv
injections of N/OFQ also have been reported [21-24].
Thus, the role of N/OFQ in anxiety and in chronic, severe
stress is still unclear. Numerous studies also have revealed
a role for N/OFQ in pain modulation. In contrast to its
antinociceptive properties upon spinal administration
[25-27], supraspinal N/OFQ produces hyperalgesia in
rats [25,28-30]. Elevated N/OFQ levels in serum were
observed in patients with acute and chronic pain [31],
but decreased N/OFQ was noted in CSF of patients re-
ceiving intrathecal morphine for pain [32], and in serum
of patients suffering from fibromyalgia, cluster headache
and migraine [33-35]. CSF and/or serum levels of N/
OFQ also were elevated in animal models of chronic
neuropathic pain [36-38]. Further, NOP antagonists
block inflammatory and neuropathic pain [39-41]. There-
fore, the second goal of this study was to determine if
changes in nociceptive sensitivity are accompanied by
changes in levels of N/OFQ. Expression of anxiety and
evidence of enhanced HPA axis feedback were assessed
to verify the validity of the SPS model in our hands.
Results from this study indicate that exposure to a se-
vere stressor can produce mechanical allodynia and ther-
mal hyperalgesia within 7 days, that is sustained for at
least another three weeks and is accompanied by
increased N/OFQ.
Results
SPS produced anxiety-like behavior and enhanced
negative feedback of the HPA axis
The SPS paradigm is a sequential exposure to four dif-
ferent stressors as described in methods: restraint, forced
swim, exposure to diethyl ether until unconscious andsocial isolation for 7 days [9,10]. The complete experi-
mental protocol is illustrated in Figure 1. To confirm
the validity of the SPS model in our hands, the assess-
ment of two symptoms of PTSD that are modeled by
SPS was made [9,14]: the appearance of anxiety-like be-
havior and enhanced negative feedback of the HPA axis.
The appearance of anxiety symptoms was examined in
control rats and rats subjected to SPS using the Elevated
plus maze (EPM) test (Figure 2). Student’s t-test
revealed that 9 days post-SPS, rats spent significantly
less time in the open arms of the EPM (p=0.0064), and
made fewer entries into open arms (p=0.0409) than con-
trol animals (Figure 2A, B; Control: n=12, SPS: n=11).
These anxiety-like behaviors cannot be explained by
reduced mobility since locomotor function was not
impaired by SPS; both groups spent equivalent time im-
mobile and travelled a comparable distance (Figure 2C,
D). Fifteen different rats were tested at day 14 after SPS
(Control: n=8, SPS: n=7). No statistical difference be-
tween groups was detected at this time point, though
the SPS rats showed a tendency to spend less time in
open arms and make fewer entries into open arms than
controls.
A cortisol suppression test was conducted to further
confirm that SPS produced enhanced negative feedback
of the HPA axis in this study as was previously reported
[9]. For this test, all rats (12) were subjected to SPS and
blood was drawn at 0, 5 and 30 min after initiation of
the first phase of SPS, the 2 hr restraint phase on day 0.
Half of the rats received a cortisol injection prior to ini-
tiation of SPS as described in methods. Nine days later,
animals were subjected to a 30 min restraint (re-stress)
accompanied by a cortisol injection, and blood was
drawn at 0, 5 and 30 min of the re-stress. On day 0,
increased plasma ACTH levels were noted at 5 and 30
min after vehicle injection (Figure 3A; n=6). The in-
crease in ACTH was significantly less in rats that
received a cortisol injection prior to restraint (n=6) than
in vehicle-treated controls (p<0.05 by Sidak’s multiple
comparisons test). Two-way repeated measures ANOVA
Figure 2 SPS produced anxiety-like behavior in EPM test. Two sets of rats were tested for 5 min duration on EPM at day 9 (control: n=12,
SPS: n=11) or 14 (control: n=8, SPS: n=7) after SPS. At day 9 SPS-exposed rats spent significantly less time in open arms (A. **p<0.01) and made
fewer entries into open arms (B. *p<0.05), consistent with anxiety-like behavior. No difference between groups was noted at day 14 after SPS. No
significant difference in total immobile time (C) or distance travelled (D) between control and SPS rats was observed at either time point.
Statistical analysis was carried out by unpaired Student’s t-test. Data are presented as mean ± SEM.
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time [F(2, 20) = 5.422, p=0.0131], indicating that cortisol
induced HPA axis negative feedback since ACTH levels
were reduced in cortisol-treated rats compared to
vehicle-treated controls (Figure 3A). There also was a
significant effect of cortisol [F(1, 10) = 9.136, p=0.0128]
and time [F(2, 20) = 71.37, p<0.0001] on ACTH levels.
Nine days after exposure to SPS, cortisol pre-treated
rats exhibited even lower ACTH response after re-stress
compared to their day 0 responses (Figure 3B). Two-
way repeated measures (by both factors) ANOVA
revealed a significant interaction between day of treat-
ment (acute vs. chronic stress/re-stress) and SPS [F(2,
10) = 6.272, p=0.0172], consistent with SPS enhance-
ment of the negative feedback of HPA axis in this study,
as was noted originally [9]. The effect of SPS [F(1, 5) =
8.767, p=0.0315] and time of collection of serum ACTH
also were significant [F(2, 10) = 21.47, p=0.0002]
(Figure 3B).
SPS induced long-lasting allodynia and hyperalgesia
To determine if pain sensitivity was altered over 21 days
following the 7 day isolation period of SPS, paw with-
drawal thresholds (PWT) to mechanical nociceptive
stimuli and paw withdrawal latencies (PWL) to thermal
nociceptive stimuli were measured at least one hourbefore initiation of SPS at day 0 and at various time
points between 7 and 28 days post-SPS as illustrated
(Figure 1: control n=12-24: SPS n=11-22). Two-way
ANOVA revealed a significant interaction between SPS
treatment and time [F(7, 240) = 11.01, p<0.0001], indi-
cating that changes in PWT differed in the two groups
over time. Basal pain thresholds (day 0) to electronic
von Frey stimuli were equivalent between groups. How-
ever, as early as day 7, SPS-exposed rats exhibited a
decreased PWT in the right hind paw compared to their
pre-SPS thresholds and to PWT in control rats. This
allodynia was sustained throughout the remainder of the
28 day study. There also was a significant effect of SPS
[F(1, 240) = 330.8, p<0.0001] and time [F(7, 240) =
12.07, p<0.0001] on PWT (Figure 4A). Specifically,
mechanical allodynia appeared at day 7 of SPS. Post-hoc
tests did not reveal differences in sensitivity within the
control group over the 28 day period, indicating that the
rats did not become sensitized to repeated assessments.
Similar results were noted with thermal stimuli as
described above for mechanical stimuli. The interaction be-
tween time and SPS treatment was significant [F(7, 233) =
7.809, p<0.0001], indicating that changes in PWL differed
over time between control and SPS rats. Two-way ANOVA
revealed a significant effect of SPS [F(1, 233) = 197.4,
p<0.0001] and time [F(7, 233) = 7.084, p<0.0001] on PWL
Figure 3 Enhanced HPA axis inhibition after SPS. (A) During the
first 30 min of the 2 hr restraint phase of SPS at day 0, cortisol pretreated
rats exhibited a significantly lower ACTH response to restraint compared
to control rats that were subjected to SPS in the absence of cortisol
injection as determined by repeated measures two-way ANOVA with
Sidak’s multiple comparisons test [F(1, 10) = 9.136, p=0.0131] (Veh, vehicle
injection. CORT, cortisol injection; n=6 for each group). (B) 9 days after
exposure to SPS, cortisol pretreated rats exhibited greater inhibition of
ACTH feedback compared to their response during the first restraint in
day 0 [F(2, 10) = 6.272, p=0.0172] (n=6). Statistical analysis was carried out
by two-way ANOVA with repeated measures (matching both factors)
followed by Sidak’s multiple comparisons test (**p<0.005). Data are
plotted as mean ± SEM.
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rats (n=11-22) had equivalent PWL to thermal stimuli at
day 0, decreased PWL of the right hind paw to thermal
stimuli also emerged at day 7 in SPS rats. This thermal
hyperalgesia lasted through day 28 compared to pre-SPS
threshold and to control rats (Figure 4B).
N/OFQ levels in serum and CSF increased during SPS
As indicated in the introduction, N/OFQ levels in serum
and CSF of humans and rats increase with some types ofacute and chronic pain, but decrease with others
[31-38], suggesting that N/OFQ plays a complex role in
pain processing. To determine if the appearance of allody-
nia and hyperalgesia are associated with changes in levels
of N/OFQ in SPS, N/OFQ levels in serum and CSF were
determined by RIA at day 9, 14 and 28 of SPS (Figure 5).
Increased N/OFQ appeared earliest in CSF (Figure 5A)
at day 9 (26.3 ± 1.0 fmol/ml in SPS rats (n=10) compared
to 19.3 ± 1.7 fmol/ml in control (n=4, p=0.0026 by un-
paired Student’s t-test). This increase was maintained at
day 14 (SPS: 25.9 ± 1.8 fmol/ml; n=8; p=0.032) and at
day 28 in SPS-treated rats (28.9 ± 3.12 fmol/ml, n=7;
p=0.009), compared to controls (day 14: 20.2 ± 1.1, n=8;
day 28: 19.6 ± 1.24 fmol/ml; n=9). An increase in serum
N/OFQ levels in SPS-exposed rats was not noted until
day 28 (272 ± 11.6 fmol/mL; n=10), which was signifi-
cantly higher than levels in control rats (n=12, 221 ± 7
fmol/mL) as determined by unpaired Student’s t-test
(Figure 5B, p=0.0008).
Decreased corticosterone levels 28 days after initiation of
SPS
Since chronic hypocortisolism has been reported in many
PTSD sufferers [42,43], the effect of SPS on the stress hor-
mone, CORT, was measured in serum from SPS and con-
trol rats euthanized on day 9, 14 or 28 (Figure 6). Mean
serum CORT levels were significantly decreased by day 28
of SPS (SPS: n=10, 107 ± 10 ng/ml) compared to control
rats (control: n=12, 144 ± 9 ng/ml) as determined by un-
paired Student’s t-test (p=0.014); No difference in serum
CORT levels between SPS and control rats on day 9 or 14
was noted.
Discussion
Considerable evidence indicates that acute stress, such
as restraint [44-46] or swimming [47], induces antinoci-
ception. In contrast, chronic stress such as chronic re-
straint, rotational or swim stress is associated with
allodynia or hyperalgesia [5-8,45,46]. However, no one
has ever examined if subjection to PTSD-like conditions
produces a painful condition or alters nociceptive sensi-
tivity over time, despite the preponderance of reports
citing increases or decreases in pain sensitivity in PTSD
patients [1,4]. Therefore, we examined changes in noci-
ceptive sensitivity to two different types of stimuli over a
three week period following the 7 day SPS paradigm
(Figure 4). Paw withdrawal thresholds to mechanical
stimuli and paw withdrawal latency in response to ther-
mal stimuli were reduced at the earliest time point
tested, 7 days after initiation of SPS, compared to con-
trol rats and to pre-SPS thresholds in SPS rats. More-
over, the increased pain responses were maintained for
at least 28 days after initiation of SPS. Correlational ana-
lysis of pain and anxiety data from SPS-treated rats on
Figure 4 Temporal Dynamics of SPS-induced mechanical allodynia (A) and thermal hyperalgesia (B). Rat PWT to von Frey stimuli (control:
n = 12–24, SPS: n = 11–22) and paw withdrawal latency (PWL) to radiant heat (control: n = 9–22, SPS: n = 9–20) dramatically decreased as early
as 7 days after SPS and lasted the length of the study, 28 days. Sensitivity in each paw differed significantly from its pre-SPS threshold; ΔΔp<0.01)
and from corresponding controls (*p<0.01; **p<0.001). Statistical analysis was carried out by two-way ANOVA followed by Sidak’s multiple
comparisons test. Data plotted as mean ± SEM.
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of allodynia and time spent in the open arms (p=0.04,
Pearson’s r= 0.662). This correlation was not evident at
day 14, when symptoms of anxiety seemed to dissipate.
Since allodynia was still present, one might argue that
the pain acted as a cue for anxiety, and that by day 14
and multiple pain assessments, the rats became condi-
tioned to the pain cue.
Previous studies reported decreased [11,14] or un-
altered [48] nociceptive sensitivity at a single time point
in the SPS model. All measured electric shock-induced
vocalization and jump thresholds in the flinch–jump test
as a metric for pain sensitivity; in one of those studies
the hot plate test also was employed [14]. Electric shock
often is employed to produce fear or anxiety and is con-
sidered a nociceptive stimulus. That particular approach
of assessing ‘pain’ sensitivity confounds the interpret-
ation of data since SPS-treated rats may freeze in re-
sponse to a foot shock conditioned stimulus, making it
difficult to ascertain if lack of response is due to reduced
nociceptive sensitivity or fear-induced immobility. The
validity of our results is further supported by the fact
that both mechanical allodynia and thermal hyperalgesia
were observed throughout a three week period instead
of a single time point.
Exposure to a high intensity stressor can induce long-
lasting physiological and behavioral changes [5,6,12]. For
example, 10–20 min of forced swimming for each of 3
days induced hyperalgesia to thermal and chemical sti-
muli 8 to 9 days after the last swim session [5]. In ano-
ther case, somatic pain sensitization was noted 4 weeks
after a single session of foot shocks [49]. The current
study indicates that SPS systematically induces long last-
ing hyperalgesia to both thermal and mechanical stimuli,
suggesting that PTSD-like conditions decrease the pain
threshold and exaggerate nociceptive sensitivity.Multiple lines of evidence suggest that endogenous
N/OFQ levels are altered with pain symptoms in humans
as well as in animal models. Serum N/OFQ levels were
increased in acute and chronic pain patients, especially
in those with chronic non-cancer pain compared to
healthy controls [31]. However, plasma N/OFQ levels
were reduced in patients suffering from fibromyalgia
syndrome, cluster headache and migraine [33-35]. In
animal models, N/OFQ levels are consistently increased
with chronic pain conditions: nerve root compression
(CSF; [36]), chronic constriction injury (serum; [37]),
streptozocin-induced diabetic neuropathy (serum; [37])
and partial sciatic nerve ligation (serum; [38]). Endoge-
nous N/OFQ also plays an important role in stress.
Acute restraint stress reduced N/OFQ content in basal
forebrain, but those neuronal stores were replenished
within 24 h, implying that stress accelerated endoge-
nous N/OFQ release and biosynthesis [50]. Acute re-
straint stress also enhanced N/OFQ expression in
hippocampus [51]. Indeed, supraspinal N/OFQ blocks
stress-induced analgesia [52]. Therefore, it was of par-
ticular interest to determine if chronic stress-induced
hyperalgesia and allodynia from SPS were associated
with changes in levels of N/OFQ in serum or CSF
when compared to control rats. Concurrent with sus-
tained mechanical allodynia and thermal hyperalgesia,
the N/OFQ content in CSF was increased by 9 days
post-SPS and remained elevated at days 14 and 28
days after initiation of SPS (Figure 5A). An increase
in serum N/OFQ was not evident until day 28
(Figure 5B). The increase was more pronounced in
CSF, in which N/OFQ increased 56% over levels in
control rats on day 9. There may be multiple sources
for the increased N/OFQ since it can be produced
and released by neuronal, glial and immune cells (for
review, see [17]). Pearson’s correlation analysis of SPS
Figure 5 SPS increased N/OFQ levels in CSF (A) and serum (B).
Serum and CSF were collected on day 9, 14 and 28 after SPS. N/OFQ
level was elevated in CSF at day 9 (control: n = 4; SPS, n = 10.
**p< 0.01), 14 (control: n = 8; SPS, n = 8. *p<0.05) and 28 (control:
n=9; SPS, n = 7, **p<0.01). Serum N/OFQ level was elevated at day 28
(control: n = 12; SPS, n = 10. **p<0.01), but not day 9 (n=4 for control;
n=10 for SPS) or 14 (n = 6/group). Statistical analysis was carried out by
unpaired Student’s t-test. Data are plotted as mean ± SEM.
Figure 6 SPS reduced long term serum CORT levels. Serum was
collected on day 9, 14 and 28 (control: n= 4, 4, 12, respectively;
SPS: n=4, 4, 10, respectively) after initiation of SPS in 3 sets of rats.
SPS exposure significantly reduced CORT levels at day 28, but not
day 9 and 14, compared to control (*p<0.01) by unpaired Student’s
t-test. Data plotted as mean ± SEM.
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OFQ levels in the CSF and allodynia at day 28 (p=
0.0109, r= 0.8701). Although it is not yet clear if ele-
vated N/OFQ is a cause, consequence or coincidence
of the increased nociceptive sensitivity, increased N/
OFQ levels in serum and CSF at 28 day after initi-
ation of SPS may reflect the broad spectrum of its
roles in stress and maintenance of the hyperalgesia
and allodynia during PTSD. Since this correlation was
not found at day 9 or 14, it may suggest that CSF N/
OFQ contributes to maintenance of a pain state that
was initially a result of the stressor. Additional studies
with NOP antagonist will be necessary to confirm if
this is the case.Rats exposed to the SPS model of PTSD exhibit
enhanced HPA axis negative feedback in response to
glucocorticoid administration [9], spend less time and
make fewer entries into open arms of the EPM [14] and
exhibit an exaggerated acoustic startle response [53],
which are consistent with physiological and behavioral
symptoms observed in PTSD patients [13]. The current
study confirmed that SPS rats spent less time and made
fewer entries into open arms of the EPM (Figure 2) and
that the HPA axis negative feedback in response to corti-
sol administration was enhanced compared to control
rats (Figure 3). These results validate the model of PTSD
in our laboratory and indicate that allodynia and hyper-
algesia were a direct result of SPS.
PTSD is associated with long-term dysregulation of
the HPA axis and abnormal cortisol levels that increased
in some studies of PTSD patients and decreased in
others [54]. In animal models of PTSD, single exposure
of an adult to a predator scent increased anxiety-like be-
havior AND plasma CORT. Exposure at both early and
later life reduced CORT levels following the initial ex-
posure, without increasing CORT levels upon re-
exposure [55]. A PTSD model involving both repeated
maternal separation and adult exposure to inescapable
foot shock increased anxiety-like behavior and reduced
basal CORT levels in plasma two months later [56].
Plasma CORT levels previously had only been assessed
in the SPS model at early times points: CORT was ele-
vated within one day of SPS initiation and returned to
baseline levels at 7 days after SPS [45,57]. The long term
effect of SPS on CORT levels has never been reported.
Our results indicate that serum CORT levels dropped
between 14 and 28 days after SPS (Figure 6), and suggest
that SPS exposure induced long-term changes in CORT.
These long-term changes parallel effects observed in
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CORT levels correlate significantly with serum N/OFQ
at day 28 (p = 0.0015, r = 0.8586). Though this relation-
ship is not yet clear, it does suggest a relationship be-
tween N/OFQ and chronic stress.
Conclusions
In conclusion, our novel findings demonstrate that ani-
mals subjected to PTSD-like conditions develop me-
chanical allodynia and thermal hyperalgesia that are
apparent from the end of the SPS period (day 7) through
at least the next 21 days (day 28). The allodynia and
hyperalgesia in SPS rats is accompanied by elevated
N/OFQ levels in CSF and serum. Though only correlative
at this point, this new evidence suggests a role for
N/OFQ in modulation of chronic stress-induced pain.
The SPS-induced up-regulation of N/OFQ suggests a
link between the N/OFQ-NOP receptor system and the
development of hyperalgesia/allodynia induced by PTSD.
Methods
Animals
Adult male Sprague–Dawley rats (n=58) weighing 220–
250 g at the initiation of SPS were obtained from
Charles River Labs (Wilmington, MA). Animals were
housed in the animal facility under a 12-h light: 12-h
dark cycle (lights on at 0600 h) with free access to food
and water. After arrival, rats were acclimated to the ani-
mal facility for 7-10 days before experiments were
initiated. Experimental protocols were approved by the
Institutional Animal Care and Use Committee of
the University of Oklahoma Health Sciences Center and
the US Army Medical Research and Materiel Command
Animal Care and Use Review Office. Research was con-
ducted in compliance with the Animal Welfare Act
Regulations and other Federal Statutes relating to ani-
mals and experiments involving animals, and adheres to
the principles set forth in the Guide for Care and Use
of Laboratory Animals, National Research Council,
1996. All experiments conformed to the guidelines of
the International Association for the Study of Pain.
Efforts were made throughout experiments to minimize
animal discomfort and reduce the number of animals
used.
SPS
Animals were randomly divided into control and SPS
groups. The SPS procedure was followed as described
[9,10] with modification. After 7 days of acclimatization,
rats were exposed to complete restraint in disposable
plastic holders for 2 hr, followed by grouped (4 rats)
forced swimming for 20 min in a cylindrical plexiglass
tank (46 cm tall × 20 cm in diameter) filled with 22°C
water to a depth of 30 cm. After 15 min recovery, ratswere exposed to diethyl ether until loss of conscious-
ness and then left isolated and undisturbed for 7 days.
SPS animals were individually housed throughout the
28 day study; control and SPS rats were assessed for
nociceptive sensitivity over the next 21 days as
described below.
Elevated plus maze (EPM) test
Some rats were tested on the EPM on day 9 or 14 after SPS
to determine the appearance of anxiety symptoms [58].
EPM tests were arranged between 0900 and 1030 h before
the pain assessment. The plus maze consisted of two open
(50 cm × 10 cm) and two closed (50 cm × 10 cm × 40 cm)
arms elevated 40 cm above floor with average light levels
40–55 lux. Each rat was placed in the center of the appa-
ratus facing the closed arms. The exposure was recorded
with a video camera for 5 min and analyzed by Any-maze
software (Stoelting Co., Wood Dale, IL). The percentage of
open arm entries (number of entries into the open arm
divided by total number of entries in both arms), the time
spent in the open arms, the total distance traveled and total
time spent immobile were calculated. None of the animals
were tested on the EPM more than once.
Pain sensitivity tests
This study examined changes in nociceptive responses
to mechanical and thermal stimuli after SPS. A plantar
analgesia meter (IITC Life Science Inc., Woodland Hills,
CA) was utilized to measure PWL to an infrared light
beam (thermal sensitivity) directed towards the right
hind paw with the lamp set at 25% active intensity. Cut-
off time was set at 30 sec to prevent tissue damage [59].
An Electronic von Frey anesthesiometer (IITC Life Science,
Inc., Woodland Hills, CA) was utilized for mechanical
nociception assessment. Rats were placed in clear plastic
boxes with a wire mesh floor and paw withdrawal thresh-
olds (PWT) were obtained from the mid-plantar aspect of
the right hind paw. The responses to thermal and me-
chanical stimuli were tested 2 h apart. The average of 3
assessments spaced 5 min apart were compared be-
tween groups for each test. SPS was initiated at least
one hour after baseline pain thresholds were assessed at
day 0. After 7 days of isolation, pain sensitivity was
assessed on days 7, 9, 12, 14, 18, 21 and 28. Rats were
euthanized at day 9 (Control = 4; SPS= 4), 14 (Control =
8; SPS= 8) and 28 (Control = 12; SPS= 10). Serum and
CSF samples were immediately taken for RIA analysis.
The experimental paradigm is illustrated by the scheme
in Figure 1.
Cortisol suppression test
Twelve rats were randomly divided into two groups of 6
rats each. Immediately following placement of each rat
into a disposable plastic holder in the first (restraint)
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vein and blood was collected into an EDTA-containing
microfuge tube to prevent coagulation and degradation
of ACTH (time 0). One group of rats was injected sub-
cutaneously with 3 mg/kg hydrocortisol, suspended in
10% ETOH + 0.9% NaCI (Sigma, St Louis, MO) imme-
diately after acquisition of the baseline blood sample,
and the other group received vehicle injection as a con-
trol. Additional blood samples were collected at 5 and
30 min of restraint. The SPS paradigm was continued as
described (Figure 1) after the 30 min data collection
point. Nine days after SPS, all rats were subjected to a
cortisol injection (3 mg/kg, s.c.) plus re-stress restraint
for 30 min. Tail nick samples were collected at 0, 5 and
30 min after restraint as noted for Day 0. SPS and tail
nick was performed between 10:00–14:00 h; each sample
was collected within 2 min. Whole blood (250~300 μl)
was obtained at each time point and centrifuged at 4°C
5,000 × g for 5 min within 30 min of collection. Rats
from this group were euthanized on day 9 after the last
blood draw; CSF was collected for N/OFQ RIA from
control rats (n=6); no pain assessments were made on
these animals.Radioimmunoassay
At day 9, 14 or 28 rats were euthanized by Beuthanasia
(Schering-Plough Animal Health, Union NJ). Blood was
withdrawn from the heart with an 18-gauge needle (be-
tween 15:00 and 17:00 h), and maintained at room
temperature for 30 min. Blood samples were centrifuged
at 5,000 × g at 4°C for 5 min and the serum was col-
lected and stored at −80°C. CSF from each rat was with-
drawn by inserting a 26-gauge needle into the cysterna
magna; CSF was immediately stored at −80°C. CORT
levels in serum were determined by kit (MP Biomedicals,
Orangeburg, NY) according to the manufacturer’s ma-
nual. The sensitivity of the assay was 25 ng/mL and
non-specific binding was 2.6%. Total amount of CORT
was calculated and expressed as ng/mL. N/OFQ content
in sera and CSF was determined by kit (Phoenix Phar-
maceuticals, Belmont, CA) according to the protocol
suggested by manufacturer, and is presented as N/OFQ-
IR. All samples and standards were assayed in duplicate.
The sensitivity of the assay was 10 pg/mL and non-
specific binding was 2.9%. There was no cross-reactivity
with dynorphin A (1–17), enkephalin or β-endorphin.
Total amount of N/OFQ was calculated and expressed
as fmol/mL. The concentration of plasma ACTH was
determined by RIA kit (MP Biomedicals, Orangeburg,
NY) according to the manufacturer’s manual. The sensi-
tivity of the assay was 10 pg/mL and non-specific bind-
ing was 4.7%. Total amount of ACTH was calculated
and expressed as pg/mL.Data analysis
Data are expressed as mean ± S.E.M. Statistical compari-
sons of behavioral and neurochemical data were per-
formed with unpaired Student’s t-test or two-way
ANOVA (with or without repeated measures as noted in
the text), followed by Sidak’s Multiple Comparisons
post-tests using GraphPad Prism 6.0 software. Corre-
lation matrices of pain thermal and mechanical pain
assessments, anxiety parameters and N/OFQ and CORT
levels were generated with data from SPS day 9, 14
and 28 rats presented herein; Pearson’s correlation
coefficient (r) and p values determined by GraphPad
Prism 6.0. Results were considered statistically signifi-
cant if p < 0.05.
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